TIDMAGL
RNS Number : 7584Y
Angle PLC
08 December 2017
For immediate release 8 December 2017
ANGLE plc ("the Company")
GROUND-BREAKING WORK DEMONSTRATES POTENTIAL FOR PARSORTIX(TM)
LIQUID BIOPSY TO REPLACE SOLID BIOPSY IN METASTATIC BREAST
CANCER
Direct comparison of a simple blood test processed with the
Parsortix system with invasive solid biopsy of the metastatic site
delivers comprehensive gene expression analysis
Leading US cancer center, the University of Southern California
Norris Comprehensive Cancer Center presents data at the
world-renowned San Antonio Breast Cancer Symposium
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is delighted to announce that the University of Southern
California (USC) Norris Comprehensive Cancer Center yesterday
presented results of extensive work with ANGLE's Parsortix(TM)
system at the San Antonio Breast Cancer Symposium (SABCS) detailing
how the system can be used to obtain comparable gene expression
information from a simple blood test in place of an invasive solid
tissue biopsy of a metastatic site.
USC made a direct comparison of extensive gene expression
information from the biopsy of the metastatic site with that from a
blood test processed with the Parsortix system. Information from
the blood test using the Parsortix system "did not show
significantly different patterns of expression" compared to the
invasive biopsy of the metastatic site. 66 clinically actionable
genes in 7 different signalling pathways were measured addressing
the key areas that clinicians currently investigate.
ANGLE is working towards an FDA clearance of the Parsortix
system in metastatic breast cancer with the required analytical and
clinical studies targeted for completion by 30 June 2018. ANGLE is
seeking to become the first company ever to receive FDA clearance
for a medical device to harvest cancer cells from patient blood for
subsequent analysis. The ground-breaking work presented by USC at
SABCS demonstrates the importance of being able to harvest and
analyse these cells from patient blood.
Julie E. Lang, MD, FACS, Director, USC Breast Cancer Program,
Associate Professor of Surgery, Norris Comprehensive Cancer Center,
University of Southern California, commented:
"Our study showed that we are able to use a Parsortix liquid
biopsy of circulating tumor cells to perform in-depth
characterization of potentially clinically actionable treatment
opportunities in metastatic breast cancer patients. We demonstrated
that circulating tumor cells may serve as a surrogate for biopsies
of macrometastases. Successful validation of our approach in future
clinical studies could revolutionize clinical management of
metastatic breast cancer and advance the promise of personalized
cancer therapies, ultimately positively changing the outcome for
patients with metastatic disease."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"USC's ground-breaking work with ANGLE's Parsortix system over
the last two years has delivered convincing data that a simple
blood test may be able to provide all the clinical information
traditionally provided by the invasive, expensive solid biopsy.
This is great news for ANGLE as it gives a clear guide to the
importance of being able to harvest and analyse these cells from
patient blood."
USC's poster for SABCS is available online at
https://angleplc.com/library/publications/. Key points are
summarised below.
The solid biopsies for comparison had to be sourced from
numerous different secondary cancer sites including skin, lung,
pleural effusion (fluid around the lung), pericardial effusion
(fluid around the heart), breast, lymph node, brain, liver,
ascites, cerebrospinal fluid (fluid found in the brain and spine)
and bone tissue. Gathering this material is an invasive surgical
procedure and many women are not well enough to undergo the
procedure.
Good RNA expression was obtained from 19/21 of the Parsortix
liquid biopsy samples, which is a level of performance that has not
been seen previously. The RNA-Seq downstream process used is one of
the "subsequent analyses" being evaluated in ANGLE's ANG-002 400
subject clinical study for FDA clearance.
The US National Cancer Institute has estimated that, as at 1
January 2017, more than 150,000 women in the United States were
living with metastatic breast cancer and this number is rising.
There is a similar level of incidence worldwide. If a regulatory
cleared blood test were available all of these women would be
candidates for such tests, repeated on a periodic basis during the
course of their metastatic disease.
ASCO (American Society of Clinical Oncology) guidelines call for
biopsy of a metastatic site to guide the decision making for
treatment as it is known that cancers change their status as
disease progresses. Access to the secondary cancer site to obtain
this tissue biopsy is challenging and requires the patient to
undergo an invasive procedure, which causes trauma and delays
treatment until they have recovered from the procedure. Furthermore
the surgical intervention takes time to arrange, is expensive and
diverts resources from care for the patient.
Consequently there is a major market need for a blood test
alternative which can provide the same or better information
non-invasively. Such a blood test would be non-invasive and could
be repeated as often as was needed.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks,
Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark for
Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is based on a patented flow through array technology. It
provides for highly multiplexed, rapid and sensitive capture of
targets from a wide variety of sample types. A proprietary
chemistry allows for the capture and amplification of over 100
biomarkers simultaneously in a single reaction. These technologies
can be combined to provide fully automated, sample to answer
results in both centralized laboratory and point of use cartridge
formats. It is ideal for measuring gene expression and other
markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future. ANGLE biomarker analysis platforms are adaptable to measure
protein and nucleic acid biomarkers across the full spectrum of
disease applications.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESBIBDDBXGBGRR
(END) Dow Jones Newswires
December 08, 2017 02:01 ET (07:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024